BTAI logo

BTAI
BioXcel Therapeutics Inc

9,750
Mkt Cap
$34.89M
Volume
349,298.00
52W High
$8.08
52W Low
$1.01
PE Ratio
-0.18
BTAI Fundamentals
Price
$1.13
Prev Close
$1.14
Open
$1.15
50D MA
$1.23
Beta
1.52
Avg. Volume
1.09M
EPS (Annual)
-$5.73
P/B
-0.29
Rev/Employee
$22,137.93
$110.18
Loading...
Loading...
News
all
press releases
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
More News
News Placeholder
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +24.64% and +16.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates
Verastem (VSTM) delivered earnings and revenue surprises of 0.00% and -16.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?
BioXcel Therapeutics (BTAI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, April 9, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no...
News Placeholder
Why Are BioXcel Therapeutics Shares Down Friday?
BioXcel Therapeutics shares fall after a rally as BXCL501 Phase 2 data show promise for treating opioid withdrawal symptoms.read more...
News Placeholder
Defense, Biotech, and Aerospace Stories Dominate
Markets are opening Thursday with a mix of defense innovation, biotech progress, aerospace supply chain momentum, and turnaround earnings, highlighting how technology and strategic manufacturing continue to drive investor attention across several sectors. From next-generation biomaterials to counter-drone systems and aerospace electronics, the latest corporate developments suggest continued capital flow toward industries tied to national security, healthcare innovation, and advanced manufacturing. $KBLB, $IBO, $GXAI, $MOBX, $BTAI, $ALTO
News Placeholder
BTAI Stock Gained 5% Today - What's The Latest On Its Opioid Withdrawal Treatment?
BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms.
News Placeholder
BioXcel Files SNDA To Expand IGALMI Label For At-Home Setting
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI) said on Tuesday that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for IGALMI, seeking approval...
News Placeholder
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. If...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available